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Background: Successful control programs have impeded local malaria transmission in almost all Gulf Cooperation
Council (GCC) countries: Qatar, Bahrain, Kuwait, Oman, the United Arab Emirates (UAE) and Saudi Arabia.
Nevertheless, a prodigious influx of imported malaria via migrant workers sustains the threat of local transmission.
Here we examine the origin of imported malaria in Qatar, assess genetic diversity and the prevalence of drug
resistance genes in imported Plasmodium falciparum, and finally, address the potential for the reintroduction of
local transmission.
Methods: This study examined imported malaria cases reported in Qatar, between 2013 and 2016. We focused on
P. falciparum infections and estimated both total parasite and gametocyte density, using qPCR and qRT-PCR,
respectively. We also examined ten neutral microsatellites and four genes associated with drug resistance, Pfmrp1,
Pfcrt, Pfmdr1, and Pfkelch13, to assess the genetic diversity of imported P. falciparum strains, and the potential for
propagating drug resistance genotypes respectively.
Results: The majority of imported malaria cases were P. vivax, while P. falciparum and mixed species infections (P.
falciparum / P. vivax) were less frequent. The primary origin of P. vivax infection was the Indian subcontinent, while
P. falciparum was mostly presented by African expatriates. Imported P. falciparum strains were highly diverse,
carrying multiple genotypes, and infections also presented with early- and late-stage gametocytes. We observed a
high prevalence of mutations implicated in drug resistance among these strains, including novel SNPs in Pfkelch13.
Conclusions: The influx of genetically diverse P. falciparum, with multiple drug resistance markers and a high
capacity for gametocyte production, represents a threat for the reestablishment of drug-resistant malaria into GCC
countries. This scenario highlights the impact of mass international migration on the reintroduction of malaria to
areas with absent or limited local transmission.
Keywords: Gulf cooperation council (GCC) countries, Imported malaria, Malaria elimination, P. falciparum,
Gametocytes, Qatar© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Hbabiker@squ.edu.om
1Department of Biochemistry, College of Medicine and Health Sciences,
Sultan Qaboos University, Muscat, Oman
7Institute of Immunology and Infection Research, School of Biological
Sciences, University of Edinburgh, Edinburgh, UK
Full list of author information is available at the end of the article
Al-Rumhi et al. BMC Infectious Diseases          (2020) 20:413 Page 2 of 10Background
The Gulf Cooperation Council (GCC) countries have
been successful in malaria control. The increased in-
vestments in control efforts beginning in the 1950s,
are largely responsible for the interruption of local
transmission, and ultimately led to malaria-free status
in four of the six GCC countries. In Saudi Arabia,
limited foci of indigenous malaria still exist [1, 2],
and in Oman sporadic outbreaks still occur periodic-
ally [3]. These successes have encouraged health min-
istries in GCC countries to shift policy toward a
malaria-free Arabian Peninsula [4] and to focus on
preventing reintroduction via sustainable vector con-
trol policy, improved surveillance, and prompt case
management [5].
Qatar has been free from local malaria transmission
since the 1970s [6], with no reports of autochthonous
malaria [7]. Despite this, the influx of migrant workers
from malaria-endemic countries of the Indian subcon-
tinent and sub-Saharan Africa has sustained a relatively
high number of imported cases, representing a major
threat for the restoration of local transmission patterns.
Migrant workers constitute the majority of residents in
most GCC countries, reaching > 80% of the populace in
Qatar [8]. Over the past two decades there has been an
increase in the flow of migrant workers to Qatar in par-
ticular. This migratory trend has been associated with a
positive trend in reported cases of imported malaria [7,
9, 10]. In addition to an increase in imported malaria,
the receptivity and risk of malaria reintroduction is evi-
dent by the continued presence of the mosquito vectors
Anopheles stephensi and An. multicolor [11].
Similar risk factors exist in other GCC countries, with
relatively high percentages of expatriates from malarious
areas. Many migrant freelance labourers from the Indian
subcontinent are subject to crowded, sub-standard living
conditions, work in stressful jobs in construction and
agriculture that undermine immune health, and live in
close proximity to irrigation sites or water tanks, thus
having an increased exposure to mosquito vectors [3]. In
Oman, there have been malaria outbreaks, presumably
seeded from imported cases, as a consequence of these
conditions, with infected individuals not identified and
treated early enough to prevent transmission to the indi-
genous Anopheles population [3].
The chronic nature of asymptomatic malaria infection,
common in adults from malaria-endemic countries, in
conjunction with population mobility, creates a threat to
effective, long-term malaria elimination [12]. Imported
asymptomatic infection often carries drug-resistant
strains of the Plasmodium parasite [9, 13], posing an
imminent threat to receptive regions where local trans-
mission has been eliminated or targeted for elimination
[14]. An improved understanding of transmissionpatterns, extending to parasite genetic diversity, and the
prevalence of drug-resistant strains of imported malaria
aids the deployment of effective cross-border mitigation
measures.
The present study examines the source of
imported malaria to the transmission-free country
of Qatar, and assesses the genetic diversity, preva-
lence of drug resistance mutations, and ability of P.
falciparum to produce gametocytes and thus be
transmitted to mosquito vectors. Such knowledge
would allow control programs to develop targeted
policies to reduce circulating parasites, define the
source of outbreaks and limit the risk of reintroduc-
tion of malaria.
Methods
Subjects
A total of 583 patients reporting to either Hamad
General Hospital or Al-Khor Hospital, two main
centers of Hamad Medical Corporation (HMC),
Doha, Qatar, were tested for malaria between Janu-
ary 2013 and October 2016. All malaria cases were
diagnosed using microscopic examination of
Giemsa-stained thick (100 fields) and thin blood
(1000 RBC) films. A total of 448 (76.8%) of subjects
tested positive for malaria, and based on disease his-
tory questionnaires, the origin of infection in all pa-
tients originated in endemic regions outside of
Qatar [15]. Genomic DNA from capillary blood was
isolated and purified using a QIAamp DNA blood-
mini kit, following the manufacturer’s instructions
(Qiagen, CA, USA). Plasmodium species identifica-
tion was confirmed using species-specific PCR, as
described elsewhere [16]. Quantitation of P. falcip-
arum was carried out by qPCR of 18 s rRNA [17].
Demographic information on each subject was
ascertained using a survey, including variables such
as age, sex, nationality, travel history, and previous
malaria diagnoses/treatments. Patients who tested
positive were provided with appropriate antimalarial
treatment, according to the current, standard guide-
lines at HMC [11].
Microsatellite genotyping and multiplicity of infection
(MOI)
A panel of ten unlinked polymorphic microsatellites of
P. falciparum were genotyped as described by Anderson
and colleagues [17, 18]. PCR products were subjected to
capillary electrophoresis using an ABI 3130XL Genetic
Analyzer (Applied Biosystems, UK). Gene Mapper soft-
ware version 4 (Applied Biosystems, UK) was used to
score allele size and quantify electropherogram peak
heights for samples containing multiple alleles per locus.
Multiple alleles per locus were scored if an
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> 32% of the height of the predominant allele [17].
Detection and quantitation of early- and late-stage P.
falciparum gametocytes
Quantitative RT-PCR (qRT-PCR) was employed to
detect and quantify mRNA from the early
gametocyte-specific gene, Pfpeg4 [19], and the late
gametocyte-specific gene, pfs25 [20]. Total RNA was
first isolated from 100 μL of capillary blood (col-
lected via finger stick) using an SV Total RNA Isola-
tion System (Promega, U.K.). Quantitative reverse
transcription and subsequent amplification (qRT-
PCR) of cDNA was carried out using a High Cap-
acity cDNA Reverse Transcription Kit (Thermo
Fisher, U.K.). RT-PCR conditions and primers were
those previously described by Hemson et al. and
Schneider et al. [21, 22].
Amplicon sequencing for the characterization of P.
falciparum drug resistance loci
SNPs in four P. falciparum genes implicated in re-
sistance to several antimalarial drugs, Pfmrp1
(PF3D7_0112200), Pfcrt (PF3D7_0709000), Pfmdr1
(PF3D7_0523000), and PfK13 (PF3D7_1343700),
were typed according to the methodology of Rao
et al. [23]. Multiplex PCR was combined with
custom-designed sequence analysis using the Illu-
mina® Miseq sequencing protocol (for the high-
throughput SNP profiling of drug resistance genes)
[23]. Seventy P. falciparum isolates were examined
together with two controls, laboratory P. falciparum
clones 3D7 and Dd2, with known alleles of the ex-
amined genes and phenotypic responses to antima-
larials [23]. The PfK13 and Pfcrt genes were each
amplified as single fragments, while the longer
Pfmdr1 and Pfmrp1genes were each amplified as
two fragments. PCR was carried out using the fol-
lowing conditions, in a total volume of 25 μl: 1 μl
(10 pmol) of primers, 0.4 μl of dNTPs (200 μmol/L),
4 μl of Phusion HF buffer (5x) and 1 U of Phusion
high-fidelity polymerase enzyme. The cycling profile
for all loci was as follows: 98 °C / 30 s, followed by
30 cycles of (98 °C / 10 s, 64 °C / 4 min.), and a final
extension of 64 °C / 5 min. The PCR amplicons of
all genes, for each isolate, were pooled and purified
using an Agencourt AMPure XP purification system
and quantified using a Qubit double-stranded DNA
(dsDNA) HS assay kit (Thermo Fisher Scientific).
Sequencing was conducted on Illumina® MiSeq sys-
tems. Initially, libraries were prepared using a Nex-
tera XT kit, according to the manufacturer’s
protocol (Illumina Nextera® XT DNA Sample Prep-
aration Guide, 2012). Following PCR cleanup,libraries were quantified using a Qubit dsDNA BR
kit, and evaluated for fragment size using an Agi-
lent High Sensitivity DNA Kit, designed for the
2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). Each library was normalized for
sequencing to 10 pM, according to the manufac-
turer’s protocol, and following Illumina’s (Illumina®,
SanDiego, CA, USA) directions for cluster
optimization (Illumina Nextera® Library Validation
and Cluster Density Optimization, 2013). Sequen-
cing reactions were carried out using a MiSeqRea-
gent Kit V2, for 50 cycles (MiSeq, Illumina). SNPs
in all genes were called using the reference se-
quence of the P. falciparum 3D7 clone, version 3
(PlasmoDB, PF3D7 v3).
Data analysis
All samples that contained gametocyte transcripts, as
detected by qRT-PCR, were assessed for association
between gametocyte carriage and total parasitemia. A
Mann-Whitney U test was used to examine the differ-
ence in density between early- and late-stage gameto-
cytes. Spearman’s rank correlation was used to test
for association between total parasite density (18S
rRNA copy number) and the density of both late-
stage gametocytes (Pfs25 copy number) and early-
stage gametocytes (Pfpeg4 copy number).
Microsatellite data was filtered to retain only minor
alleles having a peak height of > 33% of the predom-
inant allele, if more than one allele was present at a
given locus. Genetic diversity metrics were primarily
calculated using GenAlEx v6.5 [24]. Expected hetero-
zygosity was calculated using the formula for ‘un-
biased heterozygosity’ also termed haploid genetic
diversity, He = [n/(n-1)][1-Σp2], where n is the number
of isolates and p is the frequency of each allele at a
given locus [25]. Population differentiation was
assessed using Wright’s FST index in Fstat version
2.9.3.2. Two estimators of FST (G′ST and θ) [26, 27]
were used to estimate genetic differentiation between
imported parasites from the Indian subcontinent and
imported parasites from sub-Saharan Africa. Multipli-
city of infection (MOI), defined as the presence of
multiple genotypes per infection, was assessed
through the detection of multiple alleles at a given
locus. To avoid the over estimation of low-abundance
alleles, only minor alleles having a peak height of >
33% of the corresponding predominant alleles were
accepted. The proportion of samples with more than
one allele across ten loci was used to represent MOI.
The maximum number of alleles across the ten loci
was used as an index for minimum number of clones
per infection (MNC). The overall mean of the index
value for each sample was then calculated.
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Demographic characteristics of imported malaria cases in
Qatar
Among the 583 patients (all expatriates) tested for mal-
aria between January 2013 and October 2016 in Hamad
General Hospital and Al-Khor Hospital, Doha, Qatar,
448 (76.8%) tested positive for malaria: 318 for P. vivax
(70.9%), 118 for P. falciparum (26.3%) and 12 (2.7%) for
P. vivax / P. falciparum coinfection (Table 1) (Supple-
mentary Table 1).
The primary origin of those presenting with P. vivax
was the Indian subcontinent: India (46.0%, n = 146),
Pakistan (32.1%, n = 102) and Nepal (3.8%, n = 12). A
smaller proportion of P. vivax cases were from sub-
Saharan Africa (16%, n = 53) (Table 1). Unlike P. vivax,
the primary origin of P. falciparum infection was Africa:
East Africa (76.1%, n = 67), West and Central AfricaTable 1 Origin of imported malaria cases in Qatar between 2013 an
proportion of one species originating from the country listed. The in
obtained in response to the questionnaire and may not reflect all co
Qatar
Country Origin P
The Indian Subcontinent India 1
Pakistan 1
Sri Lanka 0
Nepal 1
Africa Mauritania 1
Sudan 3
Kenya 3
Nigeria 3
Eritrea 5
Ethiopia 5
Ghana 1
Rwanda 0
Cameroon 0
Tanzania 1
Djibouti 0
Democratic Republic of Congo 0
Republic of Ivory Coast 0
Chad 0
Othersa Romania 0
USA 0
Syria 0
Qatar 0
Saudi Arabia 0
Spain 0
Canada 1
Total 3
Othersa: Reported by patients who have been on a visit to malaria-endemic countri(23.9%, n = 21), followed by the Indian subcontinent
(20.3%, n = 24) and other regions (5.1%, n = 6) (Table 1).
Parasitaemia and gametocytaemia among imported
malaria cases
Ninety of the 118 P. falciparum infections were
examined for (1) total parasite density (qPCR), (2) total
gametocyte density (qRT-PCR), (3) diversity within 10
microsatellites, and (4) four genes linked to drug resist-
ance. The total P. falciparum density among imported
cases varied widely, ranging between 32 and 9,218,498
parasites/ml of blood, with a median of 82,783 parasites/
ml. The median parasite density among imported cases
from the Indian subcontinent (99,572 parasites/ml) was
not significantly different from the parasite density
among imported cases from Africa (88,504 parasites/ml)
(P = 0.394).d 2016. The percentage values in brackets represent the
formation on the originating country of the expatriates was
untries through which the individual travelled prior to arrival in
. vivax (%) P. falciparum (%) P. vivax + P. falciparum
48 (46.5%) 18 (15.3%) 2
04 (32.7%) 4 (3.4%) 0
1 (0.8%) 0
2 (3.8%) 1 (0.8%) 0
(0.3%) 0 0
4 (10.7%) 36 (30.5%) 4
(0.9%) 16 (13.6%) 3
(0.9%) 11 (9.3%) 2
(1.6%) 10 (8.5%) 1
(1.6%) 3 (2.5%) 0
(0.3%) 3 (2.5%) 0
2 (1.7%) 0
2 (1.7%) 0
(0.3%) 1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1 (0.8%) 0
1(0.8%) 0
(0.3%) 0 0
18 118 12
es
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examined by qRT-PCR to detect and quantify transcripts
of genes expressed in early- (Pfpeg4) and late-stage ga-
metocytes (Pfs25). The prevalence of all gametocytes was
74% (n = 54), with 9.6% (n = 7) of subjects possessing
only early-stage gametocytes, 37% (n = 27) possessing
only late-stage gametocytes, and 27.4% (n = 20) posses-
sing a mixture of both stages. Early- stage gametocytes
were found at a density ranging between 14 and 3781/
ml blood, with a median of 1011/ml. Late-stage gameto-
cytes were found at a density of ranging between 16 and
15,289/ml blood, with a median of 136 /ml blood).
There was a significant difference in the density of early-
and late-stage gametocyte densities (Mann-Whitney U
test, P = 0.003). There was no correlation between total
parasitaemia (18S rRNA copy number) and either late
gametocyte density (Pfs25 copy number) (rs = 0.008, P =
0.946) or early gametocyte density (Pfpeg4 copy number)
(rS = 0.031, P = 0.835) (Fig. 1).
Genetic diversity and the structure of imported P.
falciparum
Microsatellite polymorphism
All 10 microsatellites examined were highly polymorphic
for P. falciparum isolates originating in sub-Saharan Af-
rica and the Indian subcontinent (Table 2). The number
of alleles per locus was greater among African isolates,
ranging from 5 (Pfg377) to 18 (polyα), compared to iso-
lates from the Indian subcontinent, that ranged from 3
(2490) to 7 (TA1 and PfPK2) (Table 2; Supplementary
Table 2). Nevertheless, allelic diversity (defined as the
mean expected heterozygosity (He) across 10Fig. 1 Correlation between total parasite density with both early gametocy
log early gametocyte density (Y axis), the fit line in scatter plot shows a we
total parasitaemia (X axis) and log late gametocyte density (Y axis), the fit l
(r = 0.008, p = 0.946)microsatellite loci) was not significantly different among
parasites from the Indian subcontinent (mean He = 0.78)
compared to those from sub-Saharan Africa (mean He =
0.76) (P = 0.333).
Multi-locus haplotypes were constructed using pre-
dominant alleles at all examined loci. All 90 isolates dif-
fered from each other by at least one examined locus,
with the exception of two isolates from Sudan.
Multiplicity of infection (MOI)
Seventy-six (84.4%) of the 90 imported P. falciparum
isolates with complete available data possessed multiple
genotypes. The minimum number of genotypes per in-
fected person (the mean maximum number of alleles ob-
served at all loci) was slightly lower in sub-Saharan
Africa (2.16 genotypes) than the Indian subcontinent
(2.38 genotypes) (α < 0.05) (P = 0.667).
Genetic differentiation
Alleles of most P. falciparum microsatellites were dis-
tributed widely among imported malaria cases from
both sub-Saharan Africa (n = 77) and the Indian sub-
continent (n = 13). A relatively large number of pri-
vate alleles (alleles detected only in one geographic
region) were seen in Africa (n = 50) compared to the
Indian subcontinent (n = 5). This may reflect the
smaller sample size of subjects with origins in the In-
dian continent. Despite this trend, no evidence of
genetic differentiation was observed between imported
P. falciparum from sub-Saharan Africa and that
imported from the Indian subcontinent (FST = 0.055).
The genetic relatedness between P. falciparumte and late gametocyte density. a log total parasitaemia (X axis) and
ak/non-significant correlation coefficient (r = 0.031, p = 0.835). b log
ine in scatter plot shows a weak/non-significant correlation coefficient
Table 2 Number of alleles and expected heterozygosity (He) at ten microsatellite loci within imported Plasmodium falciparum from
the Indian Subcontinent and Africa
Origin of isolates 2490 Pfg377 polyα TA109 TA81 ARA2 PfPK2 TA1 TA60 TA87
The Indian Subcontinent (n = 13) Alleles 3 4 6 5 5 5 7 7 6 6
He 0.67 0.68 0.87 0.81 0.74 0.71 0.91 0.87 0.72 0.86
Africa (n = 77) Alleles 7 5 18 10 10 11 9 13 6 10
He 0.48 0.58 0.93 0.81 0.76 0.81 0.78 0.85 0..76 0.83
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which showed overlap between two populations. Ana-
lysis of molecular variance (AMOVA) within P. falcip-
arum isolates imported from the Indian subcontinent
and Africa revealed that the majority of genetic vari-
ation occurred between individuals within populations
(95%), compared to differences between populations
(P < 0.001).
Distribution of drug resistance mutations
Seventy imported P. falciparum isolates were exam-
ined by amplicon sequencing for four putative drug
resistance genes, PfK13, Pfmdr1, Pfcrt and Pfmrp1
(Table 3). With the exception of PfK13, there was
no difference in the prevalence of wild-type alleles
among parasites originating from sub-Saharan Africa
versus the Indian subcontinent. There was, however,
a significantly higher prevalence of mutant PfK13
haplotypes among parasites from Africa than the In-
dian subcontinent (P = 0.0036). One nonsynonymous
mutation in PfK13 (K189T) was observed at a preva-
lence of 36% among parasites originating from Sudan
(n = 36), similar to reported findings from other Afri-
can countries [28]. Ten additional nonsynonymous
SNPs within PfK13 were identified at prevalences
ranging from 1 to 3%: K108E (2%), L119L (1%),Fig. 2 Principal Co-ordinates Analysis (PCoA) of P. falciparum populations f
[transparent rectangular]). Values within parenthesis after the coordinate nuH136N (1%), T149S (2%), K189N (2%), N217H (1%),
R255K (3%), I354V (1%), E433D (1%) and G453A
(1%) (Table 3; Supplementary Table 3).
PfK13 variants including the substitutions C580Y,
Y493H, R539T and M579I, previously shown to be
associated with slow artemisinin clearance of P. fal-
ciparum [29, 30], were not detected among P. falcip-
arum isolates in this study. However, mutations in
the gene Pfmdr1, also associated with reduced ACT
susceptibility in some studies [31], as well as in resist-
ance to other antimalarial drugs such as chloroquine
[32], were found in the imported parasites. The
Pfmdr1 polymorphisms N86Y and Y184F were preva-
lent among imported P. falciparum isolates (33 and
77%, respectively). In addition, six rare nonsynon-
ymous SNPs were detected (see Table 3). The
N86F184D1246 and Y86F184D1246 haplotypes, associated
with artemether-lumefantrine (AL) tolerance [33] and
chloroquine/amodiaquine (CQ/AQ) treatment failure,
were reported among imported P. falciparum cases, at
43 and 33%, respectively.
Notably, while the Pfcrt K76T substitution associated
with CQR was found at a relatively low frequency (n =
70, 6%), other SNPs implicated in CQR were observed at
higher prevalence: A220S (53%), Q271E (49%), N326D/S
(36%), I356L (6%) and R371I (47%). Overall, the CQrom two regions (the Indian Subcontinent [black square] and Africa
mber are the percentage of variation explained by the coordinate
Table 3 Haplotypes of drug resistance genes, that exist at a prevalence of more than 5%, among imported P. falciparum cases in
Qatar. Haplotypes are shown as amino acids (wild-type in normal case, substitutions in bold underlined)
Locus Genotype Haplotype Prevalence the Indian subcontinent (n = 7) Africa (n = 63) P value
Pfcrt Wild type C72 K76 A220 Q271 N326 I356 R371 44% 1(14%) 30(48%) 0.1233
Mutant C72 K76 S220 E271 N326 I356 R371 13% 6(85%) 33(52%)
Mutant C/S72 T76 S220 E271 N326 I356 R371 5%
Mutant C72 K76 S220 E271 S326 I356 R371 29%
Pfmdr1 Wild type N86 F184 F938 G968 D1246 39% 4(57%) 23(37%) 0.4118
Mutant N86 Y184 F938 G968 D1246 10% 3(43%) 43(68%)
Mutant Y86 F184 F938 G968 D1246 30%
PfK13 Wild type H136 T149 K189 N217 R255 E433G453 47% 7(100%) 26(41%) 0.0036
Mutant H136 T149 T189 N217 R255 E433 G453 34% 0(0%) 37(59%)
Pfmrp1 Wild type H191K202S437I876L1342F1390 K1466D1533 31% 1(14%) 21(33%) 0.4201
Mutant H191K202S437V876L1342F1390 K1466D1533 6% 6(86%) 42(67%)
Mutant H191K202S437V876L1342F1390 R1466D1533 10%
Mutant Y191K202A437V876L1342I1390 K1466D1533 5%
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(94%), while the CQ resistant haplotypes,
S72V73M74N75T76 and C72V73M74N75T76, were detected
in only one and three isolates, respectively.
Regarding Pfmrp1, eight variants were observed among
imported P. falciparum specimens, ranging from a fre-
quency of 46% for I876V to 3% for D1533V (Table 3,
Supplementary Table 3). The five most common variants
[H191Y, S437A, I876V, F1390I, K1466R] detected
among imported cases were all previously reported in
the Indian subcontinent and Africa [34, 35], however,
they existed at a relatively higher frequency in isolates
from Africa compared to those from the Indian subcon-
tinent (Supplementary Table 3). Pfmrp1 polymorphisms
previously associated with decreased in vitro susceptibil-
ity to SP, artemisinin, mefloquine, and lumefantrine
were common. The most frequent SNP, encoding I876V
(46%), was found to be under significant selection pres-
sure following AL treatment [34].
Discussion
Sustainable interventions driven by global support have
resulted in a noteworthy global malaria case reduction
in the past three decades [5]. Twenty-one countries were
identified by the WHO for the complete elimination of
malaria by the year 2020 [36]. Drug resistance in Plas-
modium species and insecticide resistance in malaria
vectors, as well as human sociodemographic factors,
have the potential to obstruct this worthy goal. Mass
international human migration from malaria-endemic
regions where a proportion of semi-immune residents
sustain asymptomatic, low levels of parasitemia has been
shown to be a risk factor for the reintroduction of local
malaria transmission.Asymptomatic P. falciparum infection can develop
into clinical malaria in individuals up to 8 years after mi-
gration to a malaria-free country [37, 38]. Therefore,
asymptomatic migrants with malaria parasite infections
can act as a long-lasting reservoir for secondary local
transmission in receptive malaria-free areas, where elim-
ination has been accomplished [3, 39]. This potential is
evident in the high prevalence of gametocyte carriage
seen among imported P. falciparum malaria cases in
Qatar. Fifty-four of 73 imported P. falciparum isolates
(74%) examined by qRT-PCR [40] possessed gametocyte
stages, with a large proportion (37%) harboring both
early-stage and late-stage gametocytes. This trend is in-
dicative of ongoing gametocytogenesis from the asexual
population present in the patient. Low-density gameto-
cytes can readily infect Anopheles vectors, even at sub-
microscopic levels [41, 42]. Secondary transmission,
arising from imported malaria cases, is often reported in
GCC countries in areas where the Anopheles vector is
present, and a favorable ecological habitat exists [3, 43].
The surge in Anopheles abundance in highly-seasonal
transmission settings has been associated with an up-
surge in gametocyte numbers in asymptomatic carriers
[20]. This is in line with enhanced parasite infectivity in
response to increased exposure to uninfected mosqui-
toes at the start of the transmission season, in areas with
marked seasonal malaria [20, 44]. Although the resump-
tion of endemic malaria transmission in GCC countries
is unlikely given current models, the high rate of
imported malaria can readily seed outbreaks, if vector
control wanes [3].
The genetic diversity, measured as He, of P. falciparum
imported into Qatar from sub-Saharan Africa (0.76) and
the Indian subcontinent (0.78), is similar to that reported
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local transmission sites that still exist in Saudi Arabia
(0.76) and Yemen (0.585) [45]. This pattern is also found
in genotype multiplicity. These trends underscore the
role of imported malaria in enriching Plasmodium gen-
etic diversity, as well as in introducing drug resistance
lineages in areas moving towards elimination, such as
Saudi Arabia [46] and Oman [3]. Moreover, the combin-
ation of high genotype multiplicity and gametocyte car-
riage, as reported in the present study, increases the
likelihood that imported malaria infections will generate
novel genotypes, should transmission occur [47]. Thus,
imported malaria cases to Qatar represent not only a
risk for the ignition of local transmission, but also a risk
of creating novel strains that can escape the effect of
current drug regimens. Efforts to thwart the reintroduc-
tion of malaria in transmission-free areas of the GCC
currently rely on effective case management using
artemisinin-combination therapy. The present study re-
vealed a relatively high prevalence of SNPs in four un-
linked genes implicated in drug resistance, namely Pfcrt,
Pfmdr1, Pfmrp1 and PfK13.
With the exception of PfK13, there was no difference
in the distribution of drug resistance alleles between
Plasmodium parasites introduced from the Indian sub-
continent as compared to those from sub-Saharan Af-
rica. The wild type allele of PfK13 was found at high
prevalence in P. falciparum imported from sub-Saharan
Africa and the Indian subcontinent, and the variants
C580Y, Y493H, R539T, and M579I, previously associ-
ated with slow artemisinin clearance [28, 30], were not
detected.. Numerous low-frequency (1 to 3%) SNPs in
PfK13 in parasites from sub-Saharan Africa and the In-
dian subcontinent were observed(K108E, L119L, H136N,
T149S, K189N, N217H, R255K, I354V, E433D, G453A),
while one SNP, K189T, was observed at a conspicuously
higher frequency (36%) among parasites originating spe-
cifically from Sudan [28]. However, parasites carrying
mutation K189T have previously been found to have a
similar therapeutic response (parasite clearance half-life)
to ACT to wild type parasites [28], and thus may not
have an impact on the current ACT regimen in Qatar
for uncomplicated and complicated P. falciparum infec-
tion [11].
The presence of SNPs or haplotypes linked to toler-
ance of artemisinin derivatives can however impact on
current elimination strategies, potentially resulting in
persistence of symptoms and an increased local parasite
reservoir. We reported a high prevalence of the Pfmdr1-
N86F184D1246 haplotype (43%), which is associated with
reduced AL susceptibility [31]. The two most common
variants of Pfmrp1, F1390I (79%) and I876V (46%), have
been linked to a decreased susceptibility to artemisinin,
mefloquine, and lumefantrine [36, 48]. These findingssuggest that regular monitoring of the above SNPs,
coupled with an appropriate, tailored clinical response,
should be employed to combat the spread of P. falcip-
arum parasites with potential AL tolerance. Studies in
Saudi Arabia and Yemen have revealed a high frequency
of drug resistance genotypes among locally-acquired P.
falciparum infections, the source of which was linked
statistically to sub-Saharan Africa and Indian subcontin-
ent [34, 48].
A noteworthy observation from the present study was
the divergence in the frequency of Pfcrt mutation K76T
(11%) compared to mutations A220S (54%), Q271E
(50%), N326D/S (37%), and R371I (48%). Like K76T, the
latter mutations have been associated with reduction in
CQ transport activity and CQR [49]. The relatively low
frequency of the K76T mutation may reflect the fitness
cost of the variant, coupled with reduced exposure to
CQ [50], while the other mutations may carry lower fit-
ness costs and so be maintained in the population. Alter-
natively, the latter Pfcrt mutations may be under
selective pressures from both CQ and other antimalarial
drugs.Conclusions
The present study expounds upon the threat that
imported Plasmodium parasites represent for the re-
introduction of malaria in receptive, transmission-free
areas, such as Qatar. The high levels of genetic diversity
found, as well as the high capacity of imported P. falcip-
arum to produce gametocytes, highlights the threat of
spread of drug resistance genotypes, should local trans-
mission reoccur. There is an urgent need for molecular
tools, such as the highly sensitive and high-throughput
qPCR that can detect > 20 parasites/ml blood [51], for
the surveillance of imported malaria cases in Qatar and
the GCC, to limit the risk of reintroduction of malaria.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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